Literature DB >> 11518719

Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain.

S M Huang1, T Bisogno, T J Petros, S Y Chang, P A Zavitsanos, R E Zipkin, R Sivakumar, A Coop, D Y Maeda, L De Petrocellis, S Burstein, V Di Marzo, J M Walker.   

Abstract

In mammals, specific lipids and amino acids serve as crucial signaling molecules. In bacteria, conjugates of lipids and amino acids (referred to as lipoamino acids) have been identified and found to possess biological activity. Here, we report that mammals also produce lipoamino acids, specifically the arachidonyl amino acids. We show that the conjugate of arachidonic acid and glycine (N-arachidonylglycine (NAGly)) is present in bovine and rat brain as well as other tissues and that it suppresses tonic inflammatory pain. The biosynthesis of NAGly and its degradation by the enzyme fatty acid amide hydrolase can be observed in rat brain tissue. In addition to NAGly, bovine brain produces at least two other arachidonyl amino acids: N-arachidonyl gamma-aminobutyric acid (NAGABA) and N-arachidonylalanine. Like NAGly, NAGABA inhibits pain. These findings open the door to the identification of other members of this new class of biomolecules, which may be integral to pain regulation and a variety of functions in mammals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11518719     DOI: 10.1074/jbc.M107351200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  108 in total

1.  N-acyl taurines are anti-proliferative in prostate cancer cells.

Authors:  Vicky Chatzakos; Katharina Slätis; Tatjana Djureinovic; Thomas Helleday; Mary C Hunt
Journal:  Lipids       Date:  2011-12-11       Impact factor: 1.880

2.  Reversible lysine acetylation regulates activity of human glycine N-acyltransferase-like 2 (hGLYATL2): implications for production of glycine-conjugated signaling molecules.

Authors:  Dominik P Waluk; Filip Sucharski; Laszlo Sipos; Jerzy Silberring; Mary C Hunt
Journal:  J Biol Chem       Date:  2012-03-09       Impact factor: 5.157

Review 3.  The endocannabinoid system: a general view and latest additions.

Authors:  Luciano De Petrocellis; Maria Grazia Cascio; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

4.  The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief.

Authors:  Jenny L Wilkerson; Erin D Milligan
Journal:  ISRN Anesthesiol       Date:  2011

5.  Angiogenesis: a new physiological role for N-arachidonoyl serine and GPR55?

Authors:  W-S V Ho
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 6.  N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets.

Authors:  Mark Connor; Chris W Vaughan; Robert J Vandenberg
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 7.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 8.  Paracetamol: new vistas of an old drug.

Authors:  Alfio Bertolini; Anna Ferrari; Alessandra Ottani; Simona Guerzoni; Raffaella Tacchi; Sheila Leone
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

9.  Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors.

Authors:  Sandra Holt; Francesca Comelli; Barbara Costa; Christopher J Fowler
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

10.  The novel endocannabinoid receptor GPR18 is expressed in the rostral ventrolateral medulla and exerts tonic restraining influence on blood pressure.

Authors:  Anusha Penumarti; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2014-01-15       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.